Biotech | May 13, 2022
Neurocrine Biosciences receives Orphan Drug Designation for Valbenazine
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
RNAstorm and DNAstorm RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
At an affordable price, a researcher can process fresh samples of 10,000 cells immediately with a stable stopping point within two hours, simplifying sample management at the laboratory and limiting transcriptional changes
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Subscribe To Our Newsletter & Stay Updated
